Dasiglucagon - Zealand Pharma

Drug Profile

Dasiglucagon - Zealand Pharma

Alternative Names: ZP 4207; ZP-GA-1

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zealand Pharma
  • Developer Beta Bionics; Boston University; Zealand Pharma
  • Class Antihypoglycaemics; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperinsulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypoglycaemia
  • Phase II Type 1 diabetes mellitus
  • Phase I Hyperinsulinaemia

Most Recent Events

  • 07 Dec 2017 Zealand Pharma initiates a phase III trial for Hypogycaemia
  • 07 Dec 2017 Zealand Pharma plans a phase II trial for Hyperinsulinaemia (Congenital hyperinsulinism) in first half of 2018
  • 07 Dec 2017 Zealand Pharma plans a phase IIb trial for Type 1 diabetes mellitus in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top